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It has been reported that human immunodeficiency virus type 1 (HIV-1) infection may exist in
persons without specific antibodies for years. To measure the frequency of a silent carrier state, a
study was conducted in a cohort of 124 intravenous drug users (IVDUs) without anti-HIV-l
antibodies. All the participants had engaged in high-risk behavior for HIV-1 transmission for a
number of years until 1987 or later. Samples were analyzed at 6-month intervals for the presence
of HIV-l provirus using DNA amplification and for the appearance of anti-HIV-l antibodies.
HIV-1 provirus and antibodies were undetectable in 122 participants, whereas seroconversion
was observed in 2. In one of these, both amplified HIV-l pol gene segment and anti-HIV-l
antibodies were detected simultaneously, and in the other, provirus was detected 1 month before
seroconversion. This study suggests that long-term HIV-1 infection without anti-HIV-1 antibod-
ies is rare and that repeated antibody testing is sufficient to determine the HIV-1 status of a
person no longer at high risk for HIV -1 infection.
Routine testing to identify infection with human immuno-
deficiency virus type I (HIV-I) is based on the detection of
specific antibodies. The detection of antibodies is indirect
evidence of infection; direct evidence necessitates detection
of either the virus itselfor of viral components. This includes
viral culture, which is not always positive in persons known
to be infected by HIV-1 [1]. Identification of either viral
RNA or HIV-l provirus integrated into the genome of the
host provides another option. Detection of the provirus in
clinical samples can be achieved by amplification of seg-
ments of proviral DNA using the polymerase chain reaction
(PCR) [2].
Several investigators have reported PCR-positive, anti-
body-negative or viral culture-positive, antibody-negative
subjects [3-9]. These observations were made not only in
cross-sectional studies but also in individuals followed for
several months or years [3, 5, 6]. It was therefore postulated
that a silent carrier state of HIV-1 infection may exist in the
absence of antibodies for long periods of time. If true, this
might make it virtually impossible to exclude HIV -1 infec-
tion by antibody testing, even if these antibody tests were
negative months to years after exposure to HIV -1 had
ceased.
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Since 1981, we have followed a cohort of intravenous drug
users (IVDUs) on methadone treatment [10]. The aim of the
present investigation was to evaluate the existence of silent
HIV-I infection in HIV-I-negative IVDUs of this cohort
and the concordance between antibodies to HIV-I and the
detection of HI V-I DNA by PCR.
Methods
Study population. Two hundred sixty-two IVDUs on metha-
done treatment were recruited in a cohort study concerning
HIV-I infection and viral hepatitis [10]. For the present investi-
gation, seronegative IVDUs were recruited prospectively be-
tween May 1988 and November 1989. The follow-up included
biannual interviews, physical examination, and laboratory evalu-
ation. In addition, retrospective data and serum samples were
available for 1981-May 1988 for most of the participants.
Our study population was composed mainly of male IVDUs
(83%) with a mean age of 28.5 years. All were engaged in high-
risk behavior for HIV transmission for years until 1987 or later
[10]. At the first visit, 34% were HIV-I-seropositive. Of the
HIV-I-seronegative IVDUs, 64% had evidence of past hepatitis
Band 68% of hepatitis C, suggesting a high risk of contracting
hematogenous viral infections [II]. In this population, the fre-
quency of injection and needle sharing decreased after 1988
[10]. These data were confirmed for the participants of the pres-
ent study; almost 50% continue to inject and occasionally share
needles, as verified by interviews.
Control samples were collected from 40 IVDUs with anti-
HIV-I antibodies and from 20 blood donors without anti-HIV-
I antibodies.
Serology. Serum specimens were tested for anti-HlV-I anti-
bodies and p24 antigen using commercial EIAs (Abbott Labora-
tories, North Chicago). Positive EIAs were confirmed by West-
ern blot (Du Pont, Geneva).
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Figure 1. Detection of amplified human immunodeficiency
virus type I (HIV-I) DNA by autoradiography in clinical samples
and determination of sensitivity of amplication using DNA from
HIV-l-infected cell line. Left: lane A, top to bottom, samples from
four seronegative intravenous drug users (IVDUs), two blood do-
nors, and buffer control; lane B, samples from seven seropositive
IVDUs (number of copies in relation to curve established in refer-
ence to lane C varied from > 10,000 to I for 40 samples tested;
bottom sample in lane B was only sample with <3 copiesf7 X 105
peripheral blood mononuclear cells); lane C, LAV-8E5 cell line
diluted in 5 ~g of human genomic DNA to number of cell equiva-
lents per sample as listed at right of lane. Right: results of two
experiments in which 10 samples containing I, 0.3, and 0.1 cell
equivalent of LAV-8E5 cell line were added to 5 JLg of human
genomic DNA from seronegative blood donor before DNA ampli-
fication.
To measure the sensitivity of the system, DNA extracted
from the LAV-8E5 cell line containing one copy of HIV-l
provirus per cell was purified and serially diluted in human
genomic DNA to obtain 1-1000 LA V-8E5 cells per PCR
reaction (figure I, left). The sensitivity of the system was
such that one copy could be detected: A positive signal was
always detected in 15 successive experiments using the con-
trol DNA corresponding to 3 LA V-8E5 cells and, in most
instances, the sample containing DNA corresponding to I
infected cell. In addition, experiments were done on multi-
ple samples containing amounts of control positive DNA
(LAV-8E5) corresponding statistically to 1, 0.3, and 0.1 in-
fected cells (figure I, right). The results suggest that the sensi-
tivity of the system is of the order of one provirus copy per
test and that variations in positivity reflect Poisson distribu-
tion.
Initially, 155 IVDUs without anti-HlV-I antibodies were
included in the study, but some of them did not participate in
the follow-up and were excluded. A positive pol PCR signal
was not observed in any of the excluded participants.
One hundred twenty-four IVDUs on methadone treat-
ment without anti-HIV-1 antibodies were tested at regular
intervals. The length of follow-up for serology and the PCR
results are reported in table I. PCR was done twice or more
in 87 participants and once in 37 participants. In this last
group, participants had at least one negative serologic result
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Clinical samples
We have shown previously that by using PCR and the pol
primers, it was possible to identify HIV-1 pol DNA in all 40
subjects with anti-HIV-I antibodies [13]. In the present
study, genomic DNA from 40 IVDUs with anti-HIV-l anti-
bodies was amplified; all of them were pol DNA-positive on
dot blot and Southern blot, but none of the genomic DNA
from normal blood donors gave a positive pol DNA signal.
Results
Purification ofDNA. Blood (10 ml) was collected in EDTA,
and peripheral blood mononuclear cells (PBMC) were isolated
on ficoll-hypaque (Pharrnacia, Dubendorf, Switzerland). The
pellet ofPBMC was incubated overnight at 37°C in a lysis buffer
containing 100 mM NaCl, 50 mM TRIS-HCl, pH 7.5, 1 mM
EDTA, 0.5% SDS, and 100 ~g/ml proteinase K. After phenol/
chloroform extraction, DNA was precipitated with ethanol and
resuspended in 300 ~l of TE bu ffer, pH 7.4 ( 10 mM Tris, 1 mM
EDTA). The LAV-8E5 cell line, obtained through the AIDS
Research and Reference Reagent Programs (Division of AIDS,
National Institute of Allergy and Infectious Diseases, Bethesda,
MD) was grown in tissue culture as recommended, and DNA
was extracted from a pellet of 50 X 106 cells and aliquotted [12].
Amplification. An oligonucleotide primer pair in a conserved
238-bp area ofthe pol gene was selected: POL 1 (5'-TGGGTAC-
CAGCACACAAAGG) hybridizes to the minus-strand at posi-
tion 3734-3753 in HIV BRU and POL2 (5'-ACTTGTCCATG-
CA TGGCTTC) hybridizes to the plus-strand at position
3953-3972. The probe (5'-AATTGGAGAGCAATGGCTA-
GTGA), which hybridizes at position 3863-3885, was end-la-
beled with 32p.
For amplification of HI V-I segments ofpro viral DNA, a ther-
mostable DNA polymerase was used (Amplitaq DNA polymer-
ase; Perkin-Elmer Cetus, Norwalk, CT) [2] with 5 ~g ofgenomic
DNA per test and 37 cycles of amplification [13].
One-fifth volume of denatured PCR product was applied to
nylon membrane (GeneScreen Plus; NEN, Boston) using a vac-
uum filtration apparatus (Minifold II; Schleicher & Schuell,
Keene, NH). Filters were incubated for 1 h at 45°C in prehy-
bridization solution (4X SSC, 5X Denhardt's solution, 5%SDS,
20 mM sodium phosphate, pH 7, 100 ~g/ml sheared and dena-
tured salmon sperm DNA; 1X SSC = 0.15 M sodium chloride
and 0.015 M sodium citrate) and hybridized to a 32P-labeled
probe (3 X 105 cprn/rnl) by incubation at 50°C overnight. Then
filters were washed for 15 min at 50°C, once with 3X SSC and
0.1 % SDS, once with 0.5X SSC and 0.1 %SDS, then twice with
0.1 X SSC and 0.1 %SDS. Autoradiographs were obtained after 3
h and overnight exposure of X-Omat film (Kodak, Lausanne,
Switzerland) with an intensifying screen at -70°C. Southern
blot analysis was done as described [13].
Positive controls for the PCR included serially diluted DNA
of the LAV-8E5 cell line containing a single integrated copy of
HIV-l proviral DNA. Dilutions were adjusted to 5 ~g of geno-
mic human DNA (DNA purified from human white blood
cells). Other controls included buffer and DNA samples from
seronegative blood donors and seropositive IVDUs. Purification
of DNA, preparation ofsamples for PCR, and analysis ofampli-
fied products were done at three physically separated sites.
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Table 1. Follow-up testing by serology and polymerase chain re-
action (Pf.R) in 124 intravenous drug users.
Last peR result
First-known
negative EIA No. (%) Negative Positive
Before 1983 36 (29) 36 0
1984-1985 8 (6.5) 8 0
1986-1987 19 (15) 19 0
1988 48 (39) 46 2
1989 13(10.5) 13 0
Total 124 122 2
6 months before entrance into the study and one 6 months
after the PCR analysis. In 122 of 124 participants, both serol-
ogy and PCR reactions were negative.
During the observation period, two participants serocon-
verted. For one, PCR was positive in the first available DNA
sample. At that time anti-HIV-I antibodies were not detect-
able and p24 antigen was slightly positive at 5 pg/ml (3 pg/
ml is the detection limit of the p24 antigen assay). Anti-
HIV -I antibodies and p24 antigen were absent on a serum
sample collected 6 months before (no lymphocyte samples
were available at this time for PCR analysis). Anti-HIV-l
antibodies appeared I month after PCR positivity. For the
other seroconverter, PCR and serology (antibodies and p24
antigen) were negative at the first and second examinations
(months 6 and 12), but both anti-HIV-I antibodies and
PCR became positive at 18 months. No symptoms of acute
HIV-I infection were recorded by the two seroconverters ex-
cept an episode of tiredness in the second patient 3 months
before the detection of anti-HIV-I antibodies. In this pa-
tient, p24 antigen was never detectable.
In addition, seven patients that did not participate in the
present study have so far been found in our laboratory to be
pol DNA-positive before the appearance of detectable anti-
HIV-I antibodies (two of them had negative PCR results on
samples collected 2 weeks and 3 months before the collec-
tion of the PCR-positive samples). All these patients, like the
two IVDUs of the present study, developed anti-HIV-l anti-
bodies within 3 months after a PCR-positive result (data not
shown).
Discussion
One objective of the present study was to evaluate the
existence of chronic HIV-I infection using DNA amplifica-
tion of segments of the pol gene ofHI V-I provirus in a cohort
oflVDUs without detectable anti-HIV-I antibodies. The pol
oligonucleotides were selected as primers on the basis of
their low degree of sequence variation, which was less than
that of more widely used primers corresponding to other
HIV-I genes [2, 13, 13a].
Association between anti-HIV-I antibody status and the
results of DNA amplification was excellent. All 40 IVDUs
with antibodies to HIV-1 had a positive pol PCR result, and
none of the 20 seronegative blood donors had a positive pol
PCR result. Of 124 seronegative IVDUs, 122 had repeatedly
negative results for both pol PCR and anti-HIV-l antibod-
ies. For the two participants who seroconverted during the
study, there was a discrepancy between serology and pol
PCR for one ofthem, but concordant results were observed I
month later. The results in the two seroconverters of the
present study and in the seven patients found in our labora-
tory to be PCR-positive before appearance ofantibodies indi-
cate as expected that PCR can detect HIV-1 infection before
the appearance of anti-HIV-1 antibodies, but the delay be-
tween detection of the provirus and appearance of specific
antibodies was, when measurable, <6 months. In one sero-
converter, the infection was probably due to sexual contacts,
as his regular partner is infected by HIV-l; in the other, inter-
mittent use of heroin with needle-sharing seems more likely
[10]. Almost 50% of the participants of the present investiga-
tion continue to inject occasionally.
Discrepant results have been reported on seronegative
subjects belonging to high-risk groups: Imagawa et al. [3] and
others [5, 8] have reported that proviral carriage, without
specific antibodies, was common. Other investigators were
unable to demonstrate HIV -1 infection in antibody-negative
sex partners of HIV-L-infected hemophiliacs [14] or in anti-
body-negative homosexual and bisexual men [15]. On a
larger basis, the present investigation suggests that persistent
HIV-I infection without the subsequent development ofspe-
cific antibodies is uncommon in a population ofIVDUs. The
discrepant results reported can be partly related to differ-
ences in methodologies, in the recruitment of participants,
and in the length of follow-up. However, one has also to
consider the possible contamination of negative samples by
amplified segments of HIV -I-positive samples or by the
virus itself, isolation of which requires at least 10 days of
culture and numerous manipulations.
In addition, the failure to identify HIV-I may be related to
several factors. First, the IVDUs may have been recently in-
fected; however, ours was a cohort study in which most sub-
jects were followed for 2 years. Second, the virus may be
present below the treshold of detection by PCR. The system
used reproducibly detects ~3 copies ofHI V-I provirus in 7 X
105 cells, meaning that the limit of sensitivity is 3-15 HIV-I
provirus copies/rnl of blood. Repeatedly negative results
lower the theoretical limit of detection. DNA amplification
was carried out on PBMC and it is not possible to exclude
that other cell types are latently infected. However, many
data suggest that CD4 is the main host cell ofHI V-1. Finally.
we used only one pair of primers within the pol gene, and
some individuals may harbor HIV -I strains whose genome
does not hybridize to the primers selected. This is unlikely,
because it has been shown previously [13] and confirmed
here that the pol primer pair selected could amplify HIV pol
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DNA segments in all HIV-I-seropositive persons tested.
Also, the sequences of the primers selected are highly con-
served in 17 known HIV-l sequences [l3a].
In summary, the data presented here indicate that long-
term silent HIV infection is rare and that repeatedly negative
antibody testing (probably within a 6-month period) after
the last exposure is a convincing argument against HIV-l
infection.
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